All Updates

All Updates

icon
Filter
Funding
PreciseDx raises USD 20.7 million in Series B funding to advance in-depth clinical trials to validate PreciseBreast assay
Precision Medicine
Aug 21, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Product updates
Akselos introduces software for FPSO monitoring
Digital Twin
Yesterday
Partnerships
Routable partners with Convera to expand global payment capabilities for businesses
Business Expense Management
Yesterday
Product updates
Lenovo launches AI services to improve AI accessibility for any enterprise
Generative AI Infrastructure
Yesterday
Product updates
Guesty launches AI-powered website builder and review analysis tool to enhance product offering
Travel Tech
Yesterday
Product updates
Cloudera introduces new accelerators for ML project deployment
Machine Learning Infrastructure
Yesterday
Funding
Operant AI raises USD 10 million in Series A funding to boost runtime protection
Next-gen Cybersecurity
Yesterday
Funding
Aembit raises USD 25 million in Series A funding to advance IAM solutions
Identity & Access Management
Yesterday
Product updates
Saviynt launches Intelligence Suite for identity security
Identity & Access Management
Yesterday
Precision Medicine

Precision Medicine

Aug 21, 2024

PreciseDx raises USD 20.7 million in Series B funding to advance in-depth clinical trials to validate PreciseBreast assay

Funding

  • PreciseDx has raised USD 20.7 million in a Series B funding round led by Eventide Asset Management, with participation from Labcorp, Quest Diagnostics, and GenHenn Capital Venture. This brings the company's total funding to USD 31.5 million.

  • The funds will be used to advance in-depth clinical trials to validate PreciseBreast (PDxBr), an early-stage risk assessment tool for invasive breast cancer, independent of HER2 and hormone receptor status, in a targeted clinical setting and prepare for market entry.

  • Analyst QuickTake: In May 2024, Precise DX and COTA partnered with Baptist Health South Florida to assess the performance of PDxBr test for assessing the risk of invasive breast cancer recurrence. The validation assessment was expected to compare PDxBr’s results to traditional pathology reviews and 21-gene assay results. The latest funding is expected to support this clinical trial.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.